Guardant Health, Inc. is a precision oncology company that develops blood- and tissue-based diagnostic tests, data solutions, and analytics for cancer care. Its offerings support multiple stages of the oncology pathway, including screening for colorectal cancer, molecular profiling of tumors, treatment selection, monitoring for residual disease and recurrence, and research into tumor biology and therapeutic response. Products such as Guardant360, Guardant Reveal, Guardant360 Tissue, and Shield provide clinicians and researchers with genomic, epigenomic, transcriptomic, and circulating tumor DNA insights. The company also serves biopharmaceutical organizations through companion diagnostic development, clinical testing services, technology licensing, and real-world data solutions. Its software and data platforms help connect molecular findings with clinical outcomes and relevant research opportunities. Headquartered in Palo Alto, California, Guardant Health, Inc. operates across healthcare, biotechnology, clinical diagnostics, and biopharmaceutical markets, contributing to the broader use of precision medicine in cancer prevention, diagnosis, treatment, and monitoring.